The environment of pharmacovigilance regulations is constantly changing and striving for higher levels of quality.
In order to keep pace with these changes, we are always looking ahead and trying to anticipate what the future holds in terms of routine pharmacovigilance activities.
Global pharmacovigilance systems
Global pharmacovigilance systems are changing significantly due to technological progress, the increasing amount of data available to regulatory bodies and companies, as well as the increasing representation of patients in decision-making regarding health care. In the field of pharmacovigilance and regulatory compliance, pharmaceutical companies are constantly facing an increasing number of changes. These changes lead to an increased workload in terms of more intensive analysis of the growing amount of data, more extensive risk monitoring and more accurate reporting of adverse events worldwide. We believe that the key elements of pharmacovigilance of the future are smarter collection and reporting of suspected side effects and improved cooperation between regulatory authorities, patients and healthcare professionals.
How technology improves pharmacovigilance
The continuous development of digital systems enables improvements to be introduced at an astonishing rate. The adoption of technologies such as cloud solutions, mobile applications, and big data analytics technologies will further help companies move one step closer to more extensive automation of their pharmacovigilance systems. However, as much as we rely on digital innovations to improve business efficiency, we believe that the most important factor in any pharmacovigilance process is the expertise of the employees in performing the work itself.
The growing role of contract research organizations in developing and increasing the availability of medicines
The role of contract research organizations (CRO) in providing support to pharmaceutical and biopharmaceutical companies in the European Union to solve the current complex challenges in drug development has been significantly strengthened in recent years. Today, European clinical trial sponsors increasingly rely on CROs to gain data-driven insights and navigate the changing world of drug development to more effectively plan next-generation drugs. However, regardless of the latest technology available to them to optimize their business initiatives, pharmaceutical companies need a reliable consulting partner to support them throughout the entire drug life cycle. That is why PharmaVigil doo is the partner of first choice, characterized by a generous offer of consulting and regulatory services.